Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Akari Therapeutics ( (AKTX) ) has provided an announcement.
Akari Therapeutics announced the appointment of Torsten Hombeck as the new Chief Financial Officer, effective December 16, 2024. Dr. Hombeck brings extensive experience in financial leadership within the healthcare and biopharmaceutical sectors, having served in similar roles at various companies including Aspira Women’s Health and Promethera Biosciences, which enhances Akari’s strategic positioning in the financial domain.
More about Akari Therapeutics
YTD Price Performance: -68.81%
Average Trading Volume: 40,065
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $11.82M
Learn more about AKTX stock on TipRanks’ Stock Analysis page.